Daicel (4202) Q4 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2025 earnings summary
17 Jun, 2026Executive summary
Net sales for FY2025/3 rose 5.1% year-over-year to ¥586.5 billion, driven by demand recovery in automotive and electronic materials, cost reductions, and favorable exchange rates, despite certification issues at Japanese automakers.
Operating income declined 2.2% to ¥61.0 billion, ordinary profit fell 8.9% to ¥62.3 billion, and net income attributable to owners of parent dropped 11.4% to ¥49.5 billion.
EBITDA increased 6.5% to ¥102.4 billion.
Extraordinary gains from cross-shareholding sales and losses from business restructuring and impairments were recorded.
Comprehensive income decreased sharply to ¥30,946 million from ¥92,977 million the prior year.
Financial highlights
Gross profit increased to ¥164.7 billion from ¥159.3 billion year-over-year.
Free cash flow increased to ¥45.5 billion, with operating cash flow at ¥93.4 billion and investing cash flow at -¥47.9 billion.
Interest-bearing debt reduced by ¥18.0 billion; total assets decreased by ¥25.3 billion to ¥813.8 billion.
Dividend per share increased to ¥60 (from ¥50), with a payout ratio of 33.1%.
Cash and cash equivalents at year-end were ¥64.8 billion.
Outlook and guidance
FY2026/3 forecasts: net sales ¥600.0 billion (+2.3%), operating income ¥54.0 billion (-11.5%), EBITDA ¥97.0 billion (-5.3%), ordinary profit ¥54.0 billion (-10.1%), and net income ¥54.0–56.0 billion (+9.1%).
Annual dividend forecast maintained at ¥60 per share; 10 million treasury shares to be cancelled.
Company expects higher sales volume in engineering plastics and airbag inflators, but lower profits due to yen appreciation and higher depreciation.
Latest events from Daicel
- Operating income fell 25% year-over-year, but healthcare and mobility segments grew.4202
Q1 202617 Jun 2026 - Strong 1H growth driven by plastics and Smart segment, but full-year net income guidance cut.4202
Q2 202517 Jun 2026 - Sales and profits fell on FX and global headwinds, but cost controls lifted select segment margins.4202
Q2 202617 Jun 2026 - Operating profit nearly doubled on strong demand and favorable exchange rates.4202
Q1 202517 Jun 2026 - Net sales up 4.4% year-over-year, but profit margins declined amid mixed segment results.4202
Q3 202517 Jun 2026 - Profits fell on lower sales, but healthcare and safety segments showed strong growth.4202
Q3 202617 Jun 2026 - Profits fell on impairment losses, but FY2027 net income is forecast to rebound strongly.4202
Q4 202617 Jun 2026